Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10323282" target="_blank" >RIV/00064165:_____/16:10323282 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10323282

Result on the web

<a href="http://dx.doi.org/10.1111/ene.12929" target="_blank" >http://dx.doi.org/10.1111/ene.12929</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ene.12929" target="_blank" >10.1111/ene.12929</a>

Result language

angličtina

Original language name

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Original language description

Background and PurposeEarly relapse outcomes in long-term stable patients switching from interferon /glatiramer acetate (IFN/GA) to oral therapy are unknown. ObjectiveThe objective of this study was to compare early relapse and progression in multiple sclerosis (MS) patients switching to oral therapy following a period of stable disease on IFN/GA, relative to a propensity-matched comparator of patients remaining on IFN/GA. MethodsThe MSBase cohort study is a global, longitudinal registry for MS. Time to first 6-month relapse in previously stable MS patients switching from platform injectables (switchers') to oral agents were compared with propensity-matched patients remaining on IFN/GA (stayers') using a Cox marginal model. ResultsThree-hundred and ninety-six switchers were successfully matched to 396 stayers on a 1:1 basis. There was no difference in the proportion of patients recording at least one relapse in the first 1-6 months by treatment arm (7.3% switchers, 6.6% stayers; P = 0.675). The mean annualized relapse rate (P = 0.493) and the rate of first 6-month relapse by treatment arm (hazard ratio 1.22, 95% confidence interval 0.70, 2.11) were also comparable. There was no difference in the rate of disability progression by treatment arm (hazard ratio 1.43, 95% confidence interval 0.63, 3.26). ConclusionThis is the first study to compare early relapse switch probability in the period immediately following switch to oral treatment in a population previously stable on injectable therapy. There was no evidence of disease reactivation within the first 6 months of switching to oral therapy.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Neurology

ISSN

1351-5101

e-ISSN

—

Volume of the periodical

23

Issue of the periodical within the volume

4

Country of publishing house

GB - UNITED KINGDOM

Number of pages

8

Pages from-to

729-736

UT code for WoS article

000372972300014

EID of the result in the Scopus database

2-s2.0-84955062203